Antipsychotic treatment – a systematic literature review and meta-analysis of qualitative studies

Figures & data

Table 1. Quality appraisal.

	Research questions are clear	Research questions are suited to qualitative enquiry	Sample is appropriate; recruitment is clearly described	Contextual and reflective issues are acknowledged	Ethical issues are acknowledged	Method of data collection is appropriate and clearly described	Method of data analysis is appropriate and clearly described	Data analysis is rigorous and supports interpretations	Findings are clearly stated and is contextually discussed	Contributes to knowledge relevant to research questions	Overall ratings based on mode of the 10 criteria
Bjornestad et al. (2017)	++	+	++	+	+	++	++	++	++	+	+
Bjornestad et al. (2016)	++	++	++	+	+	++	++	++	++	++	++
Bülow et al. (2016)	+	+	++	+	+	+	+	–	++	++	+
Carrick et al. (2004)	++	++	++	+	+	++	++	++	++	++	++
Chang, Tao, & Lu (2013)	++	++	+	–	+	+	++	+	+	+	+
Cocoman & Casey (2018)	+	++	+	+	++	+	+	+	+	+	+
Das, Malik, & Haddad (2014)	++	+	+	–	+	++	+	+	–	+	+
Gault, Gallagher, & Chambers (2013)	++	++	+	++	++	++	++	++	++	+	+
Gee, Pearce, & Jackson (2003)	+	+	++	+	+	++	++	+	+	+	+
Geyt et al. (2017)	++	++	++	++	+	++	++	++	++	++	++
Gray & Deane (2016)	++	++	++	++	+	–	++	+	++	++	+
Hagen et al. (2010)	++	++	++	+	+	+	+	+	++	++	+
Hui et al. (2016)	+	+	++	–	+	+	+	+	+	+	+
Lorem, Frafjord, Steffensen, & Wang (2014)	++	++	++	+	+	++	+	+	++	++	++
Lloyd, Lloyd, Fitzpatrick, & Peters (2017)	++	++	++	+	+	+	++	++	++	++	++
McCann & Clark (2004)	++	++	+	+	+	+	+	+	+	+	+
Morant et al. (2017)	++	++	++	+	+	++	++	++	++	++	++
Morrison, Meehan, & Stomski (2015)	++	++	+	+	+	+	++	++	+	+	+
Murphy et al. (2015)	++	++	++	+	+	++	++	++	+	++	++
Phillips & McCann (2007)	++	++	++	+	+	+	+	+	+	+	+
Pyne et al. (2006)	++	+	++	+	+	++	++	++	+	+	+
Rogers et al. (1998)	++	++	++	+	+	+	–	–	+	+	+
Rogers, Day, Randall, & Bentall (2003)	+	++	++	+	+	+	+	+	+	+	+
Stewart et al. (2010)	++	++	++	+	+	+	++	++	++	++	++
Svedberg, Backenroth‐Ohsako, & Lützén (2003)	++	++	++	++	++	++	++	+	++	++	++
Tranulis et al. (2011)	++	++	++	+	+	+	+	+	+	+	+
Usher (2001)	++	++	+	+	+	++	++	++	++	++	++
Usher, Park, & Foster (2013)	++	++	++	+	++	++	+	+	++	++	+
Vandyk & Baker (2012)	++	++	+	+	+	+	+	+	+	+	+
Vedana & Miasso (2014)	++	++	++	+	+	++	++	++	++	++	++
Yeisen et al. (2017)	++	++	++	+	+	++	++	++	++	++	++
Zarea, Fereidooni-Moghadam, & Hakim (2016)	++	++	+	+	+	+	+	+	+	+	+

Quality criteria are based on the CASP checklist and are categorized as excellent (++), satisfactory (+), or absent (−).

Figure 1. Flow diagram of the reviewing process according to PRISMA (adapted from Moher, Liberati, Tetzlaff, & Altman, 2009).

Table 2. Number and coverage.

Meta-theme	Contributing papers	Number	Coverage
Short term benefits	Bjornestad, Davidson et al. (2017a); Bjornestad, ten Velden Hegelstad (2017); Bülow, Andersson, Denhov, & Topor (2016), Carrick et al. (2004); Chang et al. (2013); Das et al. (2014); Gault et al. (2013); Gee et al. (2003); Geyt et al. (2017); Gray & Deane (2016), Hagen et al. (2010); Hui et al. (2016); Lorem et al. (2014); Lloyd et al. (2017); Morant et al. (2017); Morrison et al. (2015); Murphy et al. (2015); Phillips & McCann (2007); Rogers et al. (1998); Svedberg et al. (2003); Tranulis et al. (2011); Usher (2001); Vedana & Miasso (2014); Yeisen et al. (2017)	23	Typical (72%)
Adverse effects and coping processes	Bjornestad, Davidson et al. (2017); Bjornestad, ten Velden Hegelstad, et al. (2017); Bülow et al. (2016), Carrick (2004); Cocoman & Casey (2018), Das et al. (2014); Gault et al. (2013); Gee et al. (2003); Geyt et al. (2017); Gray & Deane (2016), Hagen et al. (2010); Lorem et al. (2014); Lloyd et al. (2017); McCann & Clark (2004); Morant et al. (2017); Morrison et (2015); Murphy et al. (2015); Phillips & McCann (2007); Pyne et al.(2006); Rogers et al. (1998, 2003); Stewart et al. (2010); Svedberg et al. (2003); Tranulis et al. (2011); Usher (2001, Usher et al. (2013); Vandyk & Baker (2012); Vedana & Miasso (2014); Yeisen et al.(2017); Zarea et al. (2016)	30	General (94%)
Surrender and autonomy	Bjornestad, Davidson et al. (2017); Bülow et al. (2016), Carrick et al. (2004); Das et al.(2014); Gault et al. (2013); Geyt et al. (2017); Gray & Deane (2016), Hagen et al. (2010); Hui et al. (2016); Lorem et al. (2014); Lloyd et al. (2017); McCann & Clark (2004); Morant et al. (2017); Morrison et al. (2015); Murphy et al. (2015); Phillips & McCann (2007); Pyne et al. (2006); Rogers et al. (1998, 2003); Stewart et al. (2010); Svedberg et al. (2003); Tranulis et al. (2011); Usher (2001); Usher et al. (2013); Vandyk & Baker (2012); Vedana & Miasso (2014); Yeisen et al. (2017); Zarea et al. (2016)	27	General (84%)
Long-term compromise of functional recovery	Bjornestad, Davidson et al. (2017); Bjornestad, ten Velden Hegelstad, et al. (2017); Bülow et al. (2016), Cocoman & Casey (2018), Gee et al. (2003); Geyt et al. (2017); Gray & Deane (2016), Hagen et al. (2010); Hui et al. (2016); Lorem et al. (2014); Lloyd et al. (2017); McCann & Clark (2004); Morant et al. (2017); Morrison et al. (2015); Murphy et al. (2015); Pyne et al. (2006); Rogers et al. (1998); Svedberg et al. (2003); Tranulis et al. (2011); Usher (2001); Usher et al. (2013); Vedana & Miasso (2014); Zarea et al. (2016)	23	Typical (72%)

Figure 2. A first-person experimental model of anti-psychotic medication use.

Bjornestad, J., Davidson, L., Joa, I., Larsen, T. K., Hegelstad, W. T. V, Langeveld, J., … Bronnick, K. (2017). Antipsychotic treatment: Experiences of fully recovered service users. Journal of Mental Health, 1–7, 264–270. doi:10.1080/09638237.2017.1294735

 PubMed Web of Science ®Google Scholar

Bjornestad, J., Bronnick, K., Davidson, L., Hegelstad, W. T. V, Joa, I., … Melle, I. (2016). The central role of self-agency in clinical recovery from first episode psychosis. Psychosis, 1–9, 140–148. doi:10.1080/17522439.2016.1198828.

 Google Scholar

Bülow, P., Andersson, G., Denhov, A., & Topor, A. (2016). Experience of psychotropic medication–An interview study of persons with psychosis. Issues in Mental Health Nursing, 37(11), 820–828. doi:10.1080/01612840.2016.1224283

 PubMed Web of Science ®Google Scholar

Carrick, R., Mitchell, A., Powell, R. A., & Lloyd, K. (2004). The quest for well‐being: A qualitative study of the experience of taking antipsychotic medication. Psychology and Psychotherapy: Theory, Research and Practice, 77(1), 19–33. doi:10.1348/147608304322874236

 PubMedGoogle Scholar

Chang, Y. T., Tao, S. G., & Lu, C. L. (2013). Qualitative inquiry into motivators for maintaining medication adherence among Taiwanese with schizophrenia. International Journal of Mental Health Nursing, 22(3), 272–278. doi:10.1111/j.1447-0349.2012.00864.x

 PubMed Web of Science ®Google Scholar

Cocoman, A. M., & Casey, M. (2018). The physical health of individuals receiving antipsychotic medication: A qualitative inquiry on experiences and needs. Issues in Mental Health Nursing, 39(3), 282–289. doi:10.1080/01612840.2017.1386744

 PubMed Web of Science ®Google Scholar

Das, A. K., Malik, A., & Haddad, P. M. (2014). A qualitative study of the attitudes of patients in an early intervention service towards antipsychotic long-acting injections. Therapeutic Advances in Psychopharmacology, 4(5), 179–185. doi:10.1177/2045125314542098

 PubMedGoogle Scholar

Gault, I., Gallagher, A., & Chambers, M. (2013). Perspectives on medicine adherence in service users and carers with experience of legally sanctioned detention and medication: A qualitative study. Patient Preference and Adherence, 7, 787–799. doi:10.2147/PPA.S44894

 Web of Science ®Google Scholar

Gee, L., Pearce, E., & Jackson, M. (2003). Quality of life in schizophrenia: A grounded theory approach. Health and Quality of Life Outcomes, 1(1), 31. doi:10.1186/1477-7525-1-31

 PubMedGoogle Scholar

Geyt, G. L., Awenat, Y., Tai, S., & Haddock, G. (2017). Personal accounts of discontinuing neuroleptic medication for psychosis. Qualitative Health Research, 27(4), 559–572. doi:10.1177/1049732316634047

 PubMed Web of Science ®Google Scholar

Gray, R., & Deane, K. (2016). What is it like to take antipsychotic medication? A qualitative study of patients with first‐episode psychosis. Journal of Psychiatric and Mental Health Nursing, 23(2), 108–115. doi:10.1111/jpm.12288

 PubMed Web of Science ®Google Scholar

Hagen, B. F., Nixon, G., & Peters, T. (2010). The greater of two evils? How people with transformative psychotic experiences view psychotropic medications. Ethical Human Psychology and Psychiatry, 12(1), 44–59. doi:10.1891/1559-4343.12.1.44

 Google Scholar

Hui, C. L., Lo, M. C., Chan, E. H., Chen, E. S., Ko, R. W., Lee, E. H., … Chen, E. Y. (2016). Perception towards relapse and its predictors in psychosis patients: A qualitative study. Early Intervention in Psychiatry, 11(3), 224–228. doi:10.1111/eip.12378

 Google Scholar

Lorem, G. F., Frafjord, J. S., Steffensen, M., & Wang, C. E. (2014). Medication and participation: A qualitative study of patient experiences with antipsychotic drugs. Nursing Ethics, 21(3), 347–358. doi:10.1177/0969733013498528

 PubMed Web of Science ®Google Scholar

Lloyd, H., Lloyd, J., Fitzpatrick, R., & Peters, M. (2017). The role of life context and self-defined well-being in the outcomes that matter to people with a diagnosis of schizophrenia. Health Expectations: An International Journal of Public Participation in Health Care and Health Policy, 20(5), 1061–1072. doi:10.1111/hex.12548

 PubMed Web of Science ®Google Scholar

McCann, T. V., & Clark, E. (2004). Embodiment of severe and enduring mental illness: Finding meaning in schizophrenia. Issues in Mental Health Nursing, 25(8), 783–798. doi:10.1080/01612840490506365

 PubMedGoogle Scholar

Morant, N., Azam, K., Johnson, S., & Moncrieff, J. (2017). The least worst option: User experiences of antipsychotic medication and lack of involvement in medication decisions in a UK community sample. Journal of Mental Health, 27(4), 322–328. doi:10.1080/09638237.2017.1370637

 PubMed Web of Science ®Google Scholar

Morrison, P., Meehan, T., & Stomski, N. J. (2015). Living with antipsychotic medication side‐effects: The experience of Australian mental health consumers. International Journal of Mental Health Nursing, 24(3), 253–261. doi:10.1111/inm.12110

 PubMed Web of Science ®Google Scholar

Murphy, A. L., Gardner, D. M., Kisely, S., Cooke, C., Kutcher, S. P., & Hughes, J. (2015). A qualitative study of antipsychotic medication experiences of youth. Journal of the Canadian Academy of Child and Adolescent Psychiatry, 24(1), 61–69.

 Web of Science ®Google Scholar

Phillips, L., & McCann, E. (2007). The subjective experiences of people who regularly receive depot neuroleptic medication in the community. Journal of Psychiatric and Mental Health Nursing, 14(6), 578–586. doi:10.1111/j.1365-2850.2007.01145.x

 PubMed Web of Science ®Google Scholar

Pyne, J. M., McSweeney, J., Kane, H. S., Harvey, S., Bragg, L., & Fischer, E. (2006). Agreement between patients with schizophrenia and providers on factors of antipsychotic medication adherence. Psychiatric Services, 57(8), 1170–1178. doi:10.1176/appi.ps.57.8.1170

 PubMed Web of Science ®Google Scholar

Rogers, A., Day, J. C., Williams, B., Randall, F., Wood, P., Healy, D., & Bentall, R. P. (1998). The meaning and management of neuroleptic medication: A study of patients with a diagnosis of schizophrenia. Social Science & Medicine, 47(9), 1313–1323. doi:10.1016/S0277-9536(98)00209-3

 PubMed Web of Science ®Google Scholar

Rogers, A., Day, J., Randall, F., & Bentall, R. P. (2003). Patients’ understanding and participation in a trial designed to improve the management of anti-psychotic medication. Social Psychiatry and Psychiatric Epidemiology, 38(12), 720–727. doi:10.1007/s00127-003-0693-5

 PubMed Web of Science ®Google Scholar

Stewart, D. C., Anthony, G. B., & Chesson, R. (2010). ‘It's not my job. I’m the patient not the doctor’: Patient perspectives on medicines management in the treatment of schizophrenia. Patient Education and Counseling, 78(2), 212–217. doi:10.1016/j.pec.2009.06.016

 PubMed Web of Science ®Google Scholar

Svedberg, B., Backenroth-Ohsako, G., & Lützén, K. (2003). On the path to recovery: Patients’ experiences of treatment with long‐acting injections of antipsychotic medication. International Journal of Mental Health Nursing, 12(2), 110–118. doi:10.1046/j.1440-0979.2003.00277.x

 PubMed Web of Science ®Google Scholar

Tranulis, C., Goff, D., Henderson, D. C., & Freudenreich, O. (2011). Becoming adherent to antipsychotics: A qualitative study of treatment-experienced schizophrenia patients. Psychiatric Services, 62(8), 888–892. doi:10.1176/ps.62.8.pss6208_0888

 PubMed Web of Science ®Google Scholar

Usher, K. (2001). Taking neuroleptic medications as the treatment for schizophrenia: A phenomenological study. Australian and New Zealand Journal of Mental Health Nursing, 10(3), 145–155. doi:10.1046/j.1440-0979.2001.00205.x

 PubMedGoogle Scholar

Usher, K., Park, T., & Foster, K. (2013). The experience of weight gain as a result of taking second‐generation antipsychotic medications: The mental health consumer perspective. Journal of Psychiatric and Mental Health Nursing, 20(9), 801–806. doi:10.1111/jpm.12019

 PubMed Web of Science ®Google Scholar

Vandyk, A. D., & Baker, C. (2012). Qualitative descriptive study exploring schizophrenia and the everyday effect of medication‐induced weight gain. International Journal of Mental Health Nursing, 21(4), 349–357. doi:10.1111/j.1447-0349.2011.00790.x

 PubMed Web of Science ®Google Scholar

Vedana, K. G. G., & Miasso, A. I. (2014). The meaning of pharmacological treatment for schizophrenic patients. Revista Latino-Americana de Enfermagem, 22(4), 670–678. doi:10.1590/0104-1169.3427.2466

 PubMed Web of Science ®Google Scholar

Yeisen, R. A., Bjornestad, J., Joa, I., Johannessen, J. O., & Opjordsmoen, S. (2017). Experiences of antipsychotic use in patients with early psychosis: A two-year follow-up study. BMC Psychiatry, 17(1), 299. doi:10.1186/s12888-017-1425-9

 PubMedGoogle Scholar

Zarea, K., Fereidooni-Moghadam, M., & Hakim, A. (2016). Adherence to medication regimen in patients with severe and chronic psychiatric disorders: A qualitative study. Issues in Mental Health Nursing, 37(11), 868–874. doi:10.1080/01612840.2016.1239147

 PubMed Web of Science ®Google Scholar

Moher, D., Liberati, A., Tetzlaff, J., & Altman, D. G. (2009). Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. Annals of Internal Medicine, 151(4), 264–269. doi:10.7326/0003-4819-151-4-200908180-00135

 PubMed Web of Science ®Google Scholar